|Dr. Michael R. Bristow||Co-Founder, Pres, CEO & Director||320.49k||N/A||1945|
|Mr. Thomas A. Keuer||Chief Operating Officer||326.79k||N/A||1959|
|Mr. Christopher D. Ozeroff||Sr. VP, Gen. Counsel & Sec.||310.26k||N/A||1959|
|Mr. Brian L. Selby||Chief Accounting Officer & VP of Fin.||N/A||N/A||1962|
ARCA biopharma, Inc. is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic HF. It has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
ARCA biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.